ASX Announcement

19/05/2021

myriad data.
individual care.

Change of registered address

Emyria Limited (ASX: EMD) (Emyria or the Company), advises that its registered address has changed to:

D2, 661 Newcastle Street
Leederville
Western Australia 6007

The Company's postal address, contact phone number and email address are unchanged.

This announcement has been approved and authorised for release by Simon Robertson, Company Secretary of Emyria Limited.

For further information:

Dr Michael Winlo
Managing Director
(08) 6559 2800
mwinlo@emyria.com

Lexi O'Halloran
Media/Investor Relations
+ 61 (0) 404 577 076
lexi@janemorganmanagement.com.au

About Emyria (www.emyria.com)

Emyria Limited is a data-backed, drug development company. **Emyria's Treatments** target unmet needs and are focused on obtaining approval from major global regulators. Emyria's drug development programs are informed by insights generated from extensive analysis of **Emyria Data** - deep, ethically-sourced clinical evidence that is gathered with patients across Emyria's independent clinical services (**Emerald Clinics** - www.emeraldclinics.com.au)

Emyria Data provides deep treatment insights and is therefore a source of unique IP, strategically designed drug development and personalised care programs.